Hadi Manji
Research Subjects
Research Interests
Hadi Manji has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Michael Peter Lunn
National Hospital for Neurology and Neurosurgery, London, UK
4 shared publications - Gita Ramdharry
UCL Queen Square Institute of Neurology University College London London UK
2 shared publications - Julian Blake
Department of Neurophysiology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
2 shared publications - M. Laura
MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and UCLH NHS Foundation Trust, London, UK
2 shared publications - Mary M. Reilly
MRC Centre for Neuromuscular Diseases, Department of Molecular Neurosciences, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK
2 shared publications - Sinead Madeleine Murphy
Department of Neurology, Tallaght University Hospital, Dublin 24, Ireland
2 shared publications
Latest Publications
- 1 December 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (Suppl 1) , A66.2-A66
PO207 Thromboembolic risk in inflammatory neuromuscular disease patients on long-term ivig
Background Observational data suggest intravenous immunoglobulin (IVIg) increases risk of thromboembolic events (TEE). Traditional vascular risk factors influence individual risk but the pro-coagulant mechanism of IVIg is not understood. Aims To ascertain frequency of and risk factors for arterial (ATE) and venous thromboembolic events (VTE) in neuromuscular patients receiving regular IVIg. Methods Diagnosis, dose, frequency, vascular risk factors, pre and post-treatment IgG levels and plasma viscosity were recorded by retrospective casenote review. Results 112 patients received a mean (S.D) dose of 1.6 (1.2)g/kg/month, range:0.2–6.5 g/kg/month; at a mean (S.D.) interval of 4.4 (3.0) weeks, range:1–18 weeks for CIDP (58.9%), MMN (36.6%), sensory neuropathy/neuronopathy (3.7%) and myositis (0.9%). Twelve TEEs were documented during the 30 month study period (January ‘14-June ‘16); 6 MIs, 2 CVAs, and individual occurrences of TIA, DVT, PE, SVC obstruction due to central line thrombosis. TEE incidence (95% C.I.)=53.6 (30.9, 91.3)/1000 patient-years; ATE incidence=35.7 (18.2, 68.9)/1000 patient-years; VTE=22.3 (9.6–51.2)/1000 patient-years. Age (p=0.005) and QRISK2 score (p=0.01) were higher in those who had an event. There was no difference in dose/kg/month (p=0.66), or dose/g/day (p=0.28). Conclusions TEE incidence in this cohort was higher than population-based rates (TEE=7.6–7.7/1000; ATE=4.4–6.5/1000 and VTE=1.2/1000 patient-years). This analysis suggests reduction of daily dose or rate of infusion does little to mediate risk.
- 1 December 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (Suppl 1) , A66.2-A66
PO207 Thromboembolic risk in inflammatory neuromuscular disease patients on long-term ivig
Background Observational data suggest intravenous immunoglobulin (IVIg) increases risk of thromboembolic events (TEE). Traditional vascular risk factors influence individual risk but the pro-coagulant mechanism of IVIg is not understood. Aims To ascertain frequency of and risk factors for arterial (ATE) and venous thromboembolic events (VTE) in neuromuscular patients receiving regular IVIg. Methods Diagnosis, dose, frequency, vascular risk factors, pre and post-treatment IgG levels and plasma viscosity were recorded by retrospective casenote review. Results 112 patients received a mean (S.D) dose of 1.6 (1.2)g/kg/month, range:0.2–6.5 g/kg/month; at a mean (S.D.) interval of 4.4 (3.0) weeks, range:1–18 weeks for CIDP (58.9%), MMN (36.6%), sensory neuropathy/neuronopathy (3.7%) and myositis (0.9%). Twelve TEEs were documented during the 30 month study period (January ‘14-June ‘16); 6 MIs, 2 CVAs, and individual occurrences of TIA, DVT, PE, SVC obstruction due to central line thrombosis. TEE incidence (95% C.I.)=53.6 (30.9, 91.3)/1000 patient-years; ATE incidence=35.7 (18.2, 68.9)/1000 patient-years; VTE=22.3 (9.6–51.2)/1000 patient-years. Age (p=0.005) and QRISK2 score (p=0.01) were higher in those who had an event. There was no difference in dose/kg/month (p=0.66), or dose/g/day (p=0.28). Conclusions TEE incidence in this cohort was higher than population-based rates (TEE=7.6–7.7/1000; ATE=4.4–6.5/1000 and VTE=1.2/1000 patient-years). This analysis suggests reduction of daily dose or rate of infusion does little to mediate risk.
- 1 January 2013
- Published by Elsevier in Handbook of Clinical Neurology
- Vol. 115, 729-742
Drug-induced neuropathies
- 1 January 2013
- Published by Elsevier in Handbook of Clinical Neurology
- Vol. 115, 729-742
Drug-induced neuropathies
- Open Access
- 29 November 2012
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 83 (Suppl 2) , A31.4-A32
HAND WEAKNESS IN CHARCOT-MARIE-TOOTH DISEASE 1X
There have been suggestions from previous studies that patients with Charcot-Marie-Tooth disease (CMT) have weaker dominant hand muscles. Since all studies to date have included a heterogeneous group of CMT patients we decided to analyze hand strength in 43 patients with CMT1X. We recorded handedness and the MRC scores for the first dorsal interosseus (FDIO) and abductor pollicis brevis (APB) muscles, median and ulnar nerve compound motor action potentials (CMAPs) and conduction velocities in dominant and non-dominant hands. Twenty-two CMT1X patients (51%) had a weaker dominant hand; none had a stronger dominant hand. Mean MRC scores were significantly higher for FDIO and APB in non-dominant hands compared to dominant hands. Median nerve CMAPs were significantly reduced in dominant compared to non-dominant hands. We conclude that the dominant hand is weaker than the non-dominant hand in patients with CMT1X. It has been suggested in previous studies that a difference in hand strength between dominant and non-dominant hands may suggest that overwork weakness causes increased muscle weakness as the dominant hand will be used more by the patient. Whether this extrapolation is valid remains to be seen but it is an important issue as exercise training to improve strength in CMT is a growing area of research. While our study does suggest that the dominant hand is weaker in patients with CMT1X, it would be premature to suggest this is due to overwork weakness.
- 29 November 2012
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 83 (Suppl 2) , A31.4-A32
Open AccessHAND WEAKNESS IN CHARCOT-MARIE-TOOTH DISEASE 1X
There have been suggestions from previous studies that patients with Charcot-Marie-Tooth disease (CMT) have weaker dominant hand muscles. Since all studies to date have included a heterogeneous group of CMT patients we decided to analyze hand strength in 43 patients with CMT1X. We recorded handedness and the MRC scores for the first dorsal interosseus (FDIO) and abductor pollicis brevis (APB) muscles, median and ulnar nerve compound motor action potentials (CMAPs) and conduction velocities in dominant and non-dominant hands. Twenty-two CMT1X patients (51%) had a weaker dominant hand; none had a stronger dominant hand. Mean MRC scores were significantly higher for FDIO and APB in non-dominant hands compared to dominant hands. Median nerve CMAPs were significantly reduced in dominant compared to non-dominant hands. We conclude that the dominant hand is weaker than the non-dominant hand in patients with CMT1X. It has been suggested in previous studies that a difference in hand strength between dominant and non-dominant hands may suggest that overwork weakness causes increased muscle weakness as the dominant hand will be used more by the patient. Whether this extrapolation is valid remains to be seen but it is an important issue as exercise training to improve strength in CMT is a growing area of research. While our study does suggest that the dominant hand is weaker in patients with CMT1X, it would be premature to suggest this is due to overwork weakness.
- Open Access
- 1 July 2012
- Published by Elsevier in Neuromuscular Disorders
- Vol. 22 (7) , 622-626
Hand weakness in Charcot-Marie-Tooth disease 1X
- 1 July 2012
- Published by Elsevier in Neuromuscular Disorders
- Vol. 22 (7) , 622-626
Open AccessHand weakness in Charcot-Marie-Tooth disease 1X
- 1 February 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (8) , 1673-1685
Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort
The hereditary sensory and autonomic neuropathies (HSAN, also known as the hereditary sensory neuropathies) are a clinically and genetically heterogeneous group of disorders, characterised by a progressive sensory neuropathy often complicated by ulcers and amputations, with variable motor and autonomic involvement. To date, mutations in twelve genes have been identified as causing HSAN. To study the frequency of mutations in these genes and the associated phenotypes, we screened 140 index patients in our inherited neuropathy cohort with a clinical diagnosis of HSAN for mutations in the coding regions of SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 (TRKA) and NGFB. We identified 25 index patients with mutations in six genes associated with HSAN (SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 and NGFB); 20 of which appear to be pathogenic giving an overall mutation frequency of 14.3%. Mutations in the known genes for HSAN are rare suggesting that further HSAN genes are yet to be identified. The p.Cys133Trp mutation in SPTLC1 is the most common cause of HSAN in the UK population and should be screened first in all patients with sporadic or autosomal dominant HSAN.
- 1 February 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (8) , 1673-1685
Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort
The hereditary sensory and autonomic neuropathies (HSAN, also known as the hereditary sensory neuropathies) are a clinically and genetically heterogeneous group of disorders, characterised by a progressive sensory neuropathy often complicated by ulcers and amputations, with variable motor and autonomic involvement. To date, mutations in twelve genes have been identified as causing HSAN. To study the frequency of mutations in these genes and the associated phenotypes, we screened 140 index patients in our inherited neuropathy cohort with a clinical diagnosis of HSAN for mutations in the coding regions of SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 (TRKA) and NGFB. We identified 25 index patients with mutations in six genes associated with HSAN (SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 and NGFB); 20 of which appear to be pathogenic giving an overall mutation frequency of 14.3%. Mutations in the known genes for HSAN are rare suggesting that further HSAN genes are yet to be identified. The p.Cys133Trp mutation in SPTLC1 is the most common cause of HSAN in the UK population and should be screened first in all patients with sporadic or autosomal dominant HSAN.
- 31 March 2010
- Published by Elsevier in Neuromuscular Disorders
- Vol. 20, S19-S20
P55 Neurophysiological evidence for cerebellar dysfunction in neuropathic tremor
- 31 March 2010
- Published by Elsevier in Neuromuscular Disorders
- Vol. 20, S19-S20
P55 Neurophysiological evidence for cerebellar dysfunction in neuropathic tremor
- Open Access
- 1 March 2004
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (90001) , 29i-35
THE NEUROLOGY OF HIV INFECTION
- 1 March 2004
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (90001) , 29i-35
Open AccessTHE NEUROLOGY OF HIV INFECTION